Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity-Reference-Cited by-同舟云学术

Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity

Published:2019-06 Issue:6 Volume:104 Page:1158-1168
ISSN:0002-9297
Container-title:The American Journal of Human Genetics
language:en
Short-container-title:The American Journal of Human Genetics

Author:

Fragoulakis Vasileios,Roncato Rossana,Fratte Chiara Dalle,Ecca Fabrizio,Bartsakoulia Marina,Innocenti Federico,Toffoli Giuseppe,Cecchin Erika,Patrinos George P.,Mitropoulou Christina

Funder

European Commission

Publisher

Elsevier BV

Subject

Genetics (clinical),Genetics

Reference34 articles.

1. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil;Johnson;Adv. Enzyme Regul.,2001

2. Is It Finally Time for a personalized medicine approach for Fluorouracil-based therapies?;Offer;J. Clin. Oncol.,2016

3. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis;Henricks;Lancet Oncol.,2018

4. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147);Lee;J. Natl. Cancer Inst.,2014

5. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines;Toffoli;Int. J. Cancer,2015

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diversity of oncopharmacogenetic profile within Spanish population;Pharmacogenetics and Genomics;2024-03-18

2. Clinical implementation of preemptive pharmacogenomics in psychiatry;eBioMedicine;2024-03

3. Assessing the Utility of Measurement Methods Applied in Economic Evaluations of Pharmacogenomics Applications;Pharmacogenomics;2024-01

4. Germline pharmacogenomics in cancer treatment;Diagnostic Molecular Pathology;2024

5. Implementation of pre‐emptive testing of a pharmacogenomic panel in clinical practice: Where do we stand?;British Journal of Clinical Pharmacology;2023-12-21